Elgin woman's book chronicles taking care of her mother with Alzheimer's, who believed their roles were reversed and that the author was her mom.
Pam Singleton never gave birth to a child. But that ultimately didn't stop her from being a mother, even in a most unlikely manner.
by signing up you agree to our terms of service "I would cry all the way home," she said."I'd get there and think, 'I'm not going to be able to maintain this.' It's just so draining."
From that point, Singleton's approach to caregiving -- and the satisfaction both got from it -- changed.
Singleton said she saw the role reversal as beneficial to both of them. Her mom was less anxious, and Singleton was more able to focus on the positives.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Iowa Alzheimer's care facility is fined $10,000 after pronouncing a living woman deadThe woman was unresponsive, and nurses were unable to detect her breathing. A state agency report found the facility 'failed to ensure residents received dignified treatment and care at end of life.'
Lire la suite »
Iowa Alzheimer's care facility is fined $10,000 after pronouncing a living woman deadThe woman was unresponsive, and nurses were unable to detect her breathing. A state agency report found the facility 'failed to ensure residents received dignified treatment and care at end of life.'
Lire la suite »
Why a new Alzheimer’s drug is having a slow U.S. debutThe first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems.
Lire la suite »